Semaglutide and PCOS weight loss: what the evidence actually supports

What did @maicyrobison actually say?

Straightforwardly: nothing medical. The transcript is song lyrics, not health commentary. Lines like "first class how I get around the world" and "unless you come in with the commas" are rap or pop lyrics, almost certainly playing in the background or lip-synced over a transformation video. There are zero spoken claims about semaglutide, tirzepatide, PCOS, weight loss, or GLP-1 medications anywhere in the transcript.

The caption does the heavier lifting here. "Still can't get over my transformation!!" paired with hashtags like #semaglutide, #compoundedsemaglutide, and #pcos tells the audience this is a before-and-after video attributed to GLP-1 use. But the creator never verbally explains a mechanism, a dose, a timeline, or a health outcome. What we have is a visual testimonial with a musical soundtrack, not a medical tutorial.

Does the science back this up?

There is no specific claim to evaluate against the literature, but the implicit message, that GLP-1 receptor agonists produced a visible body transformation, is broadly consistent with the evidence. That part is fair.

Semaglutide's weight loss efficacy is well-documented. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that once-weekly subcutaneous semaglutide 2.4mg produced mean body weight reduction of 14.9% over 68 weeks in adults with obesity, compared to 2.4% with placebo. Tirzepatide data is even more striking: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 20.9% mean weight reduction at the highest dose. Visible transformation over months of treatment is not surprising given these numbers. The hashtag #pcos also gestures at a real area of emerging research. Small trials and observational data suggest GLP-1 agonists may improve metabolic markers in women with polycystic ovary syndrome, though this is not an FDA-approved indication and the evidence base is thinner than for general obesity treatment.

What did they get wrong (or right)?

Nothing was explicitly wrong because nothing was explicitly stated. That is both the defense and the problem with this format. Transformation videos that credit a drug category without explaining risks, realistic outcomes, or medical supervision do real work in shaping audience expectations, even when the creator never opens their mouth about dosing.

The compounded semaglutide hashtag warrants attention. Compounded semaglutide is not FDA-approved, and the FDA has repeatedly warned that compounded versions are not demonstrated to be equivalent to brand-name Wegovy or Ozempic in safety or efficacy. The agency issued a drug shortage-related enforcement policy that allowed compounding during the shortage period, but that status has been contested and updated. Implicitly associating a dramatic transformation with compounded semaglutide, without any disclaimer, is not technically wrong but it is not the full picture either.

Credit where it is due: the creator is not selling anything in the transcript, not claiming a cure, and not advising followers to take a specific dose. That is a lower bar than it sounds, but plenty of GLP-1 creators clear it in the wrong direction.

What should you actually know?

If you watched this video and thought "I want those results," here is what the research actually says about what drives outcomes on GLP-1 therapy.

• Individual response varies widely. STEP 1 showed impressive mean results, but roughly 14% of participants lost less than 5% of body weight on semaglutide. A viral transformation is a best-case anecdote, not a guarantee.
• Compounded semaglutide is not the same as Wegovy. The FDA has been explicit: compounded drugs do not undergo the same approval process, and purity, potency, and sterility are not federally verified the same way. Patients using compounded versions should do so under physician supervision, period.
• PCOS is a real area of investigation for GLP-1s. A 2023 systematic review (Xing et al., Frontiers in Endocrinology) found improvements in BMI, insulin resistance, and androgen levels in women with PCOS using GLP-1 agonists, but sample sizes were small and most studies short. This is promising, not proven.
• Stopping GLP-1 medication typically reverses most weight loss. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants regained two-thirds of lost weight within a year of discontinuation. Transformation videos rarely show that part.

The bottom line on this video

This is a song-over-transformation post, not a medical explainer. The implicit claim, GLP-1 therapy produced meaningful weight loss, is supported by solid clinical trial data. The specific hashtag for compounded semaglutide deserves more scrutiny than a caption can provide. No false medical claims were made verbally, but absence of misinformation is not the same as adequate context for 851,000 viewers making real health decisions.